New hope for tough lung cancer: BL-B01D1 takes on topotecan in phase 3 trial
NCT ID NCT06500026
First seen Apr 24, 2026 · Last updated May 19, 2026 · Updated 4 times
Summary
This study compares a new drug, BL-B01D1, to the standard drug topotecan in 722 adults with small cell lung cancer that came back after prior treatments. The goal is to see if BL-B01D1 helps people live longer. Participants must have already tried immunotherapy and chemotherapy without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.